EDITAS MEDICINE INC (EDIT) Stock Price & Overview
NASDAQ:EDIT • US28106W1036
Current stock price
The current stock price of EDIT is 3.32 USD. Today EDIT is up by 0.61%. In the past month the price increased by 37.5%. In the past year, price increased by 114.29%.
EDIT Key Statistics
- Market Cap
- 324.928M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.89
- Dividend Yield
- N/A
EDIT Stock Performance
EDIT Stock Chart
EDIT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is one of the better performing stocks in the market, outperforming 94.85% of all stocks.
EDIT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT may be in some trouble as it scores bad on both profitability and health.
EDIT Earnings
On March 9, 2026 EDIT reported an EPS of -0.06 and a revenue of 24.74M. The company beat EPS expectations (77.22% surprise) and beat revenue expectations (333.52% surprise).
EDIT Forecast & Estimates
20 analysts have analysed EDIT and the average price target is 5.52 USD. This implies a price increase of 66.21% is expected in the next year compared to the current price of 3.32.
For the next year, analysts expect an EPS growth of 44.29% and a revenue growth 24.19% for EDIT
EDIT Groups
Sector & Classification
EDIT Financial Highlights
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS increased by 34.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.81% | ||
| ROE | -586.56% | ||
| Debt/Equity | 1.96 |
EDIT Ownership
EDIT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.58 | 362.808B | ||
| AMGN | AMGEN INC | 15.09 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 14.88 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.45 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.9 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.41 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.81 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.8 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EDIT
Company Profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Company Info
IPO: 2016-02-03
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 87
Phone: 16174019000
EDITAS MEDICINE INC / EDIT FAQ
Can you describe the business of EDITAS MEDICINE INC?
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
What is the current price of EDIT stock?
The current stock price of EDIT is 3.32 USD. The price increased by 0.61% in the last trading session.
What is the dividend status of EDITAS MEDICINE INC?
EDIT does not pay a dividend.
What is the ChartMill technical and fundamental rating of EDIT stock?
EDIT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of EDIT stock?
EDITAS MEDICINE INC (EDIT) operates in the Health Care sector and the Biotechnology industry.
How many employees does EDITAS MEDICINE INC have?
EDITAS MEDICINE INC (EDIT) currently has 87 employees.
What is EDITAS MEDICINE INC worth?
EDITAS MEDICINE INC (EDIT) has a market capitalization of 324.93M USD. This makes EDIT a Small Cap stock.